Metformin Milpharm (Metformin Hydrochloride)

Metformin Milpharm belongs to the biguanide class and is used to manage disorders of glucose metabolism.

• Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels to improve overall glycaemic control.
• Prediabetes: reduces the risk of progression to overt diabetes by enhancing insulin sensitivity.
• Polycystic ovary syndrome (PCOS): helps mitigate insulin resistance, which can improve ovulatory function and hormonal balance.

• Metformin Hydrochloride reduces hepatic gluconeogenesis and increases peripheral glucose uptake by activating AMP‑activated protein kinase (AMPK). This leads to decreased liver glucose output and improved insulin sensitivity in muscle and adipose tissue, resulting in lower circulating glucose levels without directly stimulating insulin secretion.

Metformin Milpharm may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: loose stools, often early in therapy.
• Abdominal discomfort: cramping or bloating.
• Metallic taste: transient alteration of taste perception.
• Decreased appetite: reduced desire to eat.
• Flatulence: increased intestinal gas.

Serious or Rare Side Effects

• Lactic acidosis: a rare but life‑threatening accumulation of lactate.
• Severe skin reactions: such as Stevens‑Johnson syndrome.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Hypoglycaemia: uncommon when used alone but possible with other glucose‑lowering agents.
• Pancreatitis: inflammation of the pancreas.

Before initiating Metformin Milpharm, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

• Renal function: assess creatinine clearance and avoid use in severe renal impairment.
• Hepatic function: evaluate liver enzymes; avoid in active liver disease.
• Risk of lactic acidosis: consider contraindications such as hypoxia, sepsis, or alcohol abuse.
• Elderly patients: start at lower doses and monitor tolerance closely.
• Concomitant medications: review for drugs that may affect renal clearance or increase lactate production.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metformin Hydrochloride can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Iodinated contrast agents: can precipitate acute renal failure and increase lactic acidosis risk.
• Cimetidine: may raise metformin plasma concentrations.
• Alcohol: enhances risk of lactic acidosis.
• Rifampicin: reduces metformin exposure, potentially diminishing glucose‑lowering effect.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycaemia symptoms.
• Diuretics: can affect renal clearance of metformin.
• ACE inhibitors/ARBs: monitor renal function and potassium levels.
• NSAIDs: may impair renal function, increasing metformin levels.
• Warfarin: occasional reports of altered INR; monitor coagulation status.